These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 5121313)

  • 1. Immunogenic enhancement by neuraminidase.
    Oxley S; Griffen WO
    Surg Forum; 1971; 22():113-4. PubMed ID: 5121313
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas.
    Simmons RL; Rios A
    J Immunol; 1973 Dec; 111(6):1820-5. PubMed ID: 4750868
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuraminidase and concanavalin A in the experimental immunotherapy of cancer.
    Simmons RL; Rios A
    Johns Hopkins Med J Suppl; 1974; 3():75-84. PubMed ID: 4536589
    [No Abstract]   [Full Text] [Related]  

  • 4. Transplantability and antigenicity of two sublines of the TA3 tumor.
    Sanford BH; Codington JF; Jeanloz RW; Palmer PD
    J Immunol; 1973 May; 110(5):1233-7. PubMed ID: 4572632
    [No Abstract]   [Full Text] [Related]  

  • 5. Karyotypic and surface features of murine TA3 carcinoma cells during immunoselection in mice and rats.
    Hauschka TS; Weiss L; Holdridge BA; Cudney TL; Zumpft M; Planinsek JA
    J Natl Cancer Inst; 1971 Aug; 47(2):343-59. PubMed ID: 4934423
    [No Abstract]   [Full Text] [Related]  

  • 6. Antigen specificity and immunogenic capacity of 3m KCl cell extracts from ascites tumour ATPCplus.
    Marconi P; Bistoni F; Pitzurra M
    Boll Ist Sieroter Milan; 1974; 53(2):377-91. PubMed ID: 4214542
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation between tumor-specific systemic and in situ immunity as manifested by the delayed hypersensitivity response.
    Radov LA; Haskill JS; Korn JH; Fett JW
    J Natl Cancer Inst; 1979 Jan; 62(1):103-8. PubMed ID: 281564
    [No Abstract]   [Full Text] [Related]  

  • 8. Adenocarcinoma associated antigen: enhancement of tumor growth with serum from animals bearing adenocarcinoma.
    Hakin AA
    Surg Forum; 1975; 26():175-7. PubMed ID: 1216104
    [No Abstract]   [Full Text] [Related]  

  • 9. The development of cellular immunity to tumor cells.
    Cerilli J; Smith MC
    Surg Gynecol Obstet; 1972 May; 134(5):739-45. PubMed ID: 5064081
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor therapy of neoplastic diseases with tumor cells and neuraminidase: experimental studies on chessboard vaccination in transplantation tumors.
    Sedlacek HH; Bengelsdorff KH; Hagmayer G; Seiler FR
    Int J Immunopharmacol; 1987; 9(7):841-50. PubMed ID: 3429076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunogenic activity of tumor antigens retained by the reticuloendothelial cells of tumor-bearing mice.
    Vaage J
    Cancer Res; 1972 May; 32(5):898-903. PubMed ID: 5017740
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune response to inactivated syngeneic mammary adenocarcinoma cells. II. Parameters of immunogenicity in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):131-7. PubMed ID: 6928038
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of an immunoresistant and an immunosusceptible ascites subline from murine tumor TA3. I. Transplantability, morphology, and some physicochemical characteristics.
    Friberg S
    J Natl Cancer Inst; 1972 May; 48(5):1463-76. PubMed ID: 5030958
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunity to a TA3 tumor subline that grows in allogeneic hosts elicited by strain-specific TA3 tumor cells.
    Lippman MM; Venditti JM; Kline I; Elam DL
    Cancer Res; 1973 Apr; 33(4):679-84. PubMed ID: 4696468
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuraminidase treated cells and their role in cancer immunotherapy.
    Simmons RL; Rios A
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):223-8. PubMed ID: 4611534
    [No Abstract]   [Full Text] [Related]  

  • 16. [Solubilization of antigens from ATPC+ ascitic tumor using hypertonic sodium solution].
    Marconi P; Bistoni F; Pitzurra M
    Boll Soc Ital Biol Sper; 1973 May; 49(10):534-8. PubMed ID: 4132962
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection of tumour-associated transplantation antigen of BO-IV carcinoma on somatic cells of tumour-free syngeneic mice. II. Search for a common antigen in some organs and spontaneous mammary carcinomas.
    Rejthar A; Wotke J
    Folia Biol (Krakow); 1973; 21(1):52-7. PubMed ID: 4693119
    [No Abstract]   [Full Text] [Related]  

  • 18. Survival of 125IUDR labeled tumour cells in the blood stream.
    Pitzurra M; Marconi P; Bistoni F; Palumbo R; Corso S
    Boll Ist Sieroter Milan; 1973; 52(4):349-56. PubMed ID: 4777700
    [No Abstract]   [Full Text] [Related]  

  • 19. A tumour-associated membrane antigen transiently expressed by normal cells during mitosis.
    Bertini M; Forni G; Comoglio PM
    Clin Exp Immunol; 1974 Sep; 18(1):101-8. PubMed ID: 4468189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cycling of immune responses to a syngeneic murine mammary adenocarcinoma.
    Huber SA; Bigi G; Lucas ZJ
    Cancer Res; 1980 Oct; 40(10):3484-90. PubMed ID: 6449282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.